BACKGROUND: Contemporary descriptions of classical Hodgkin lymphoma (cHL) are lacking from sub-Saharan Africa where human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV) are prevalent. METHODS: We describe a prospective cHL cohort in Malawi enrolled from 2013 to 2015. Patients received standardized treatment and evaluation, including HIV status and EBV testing of tumors and plasma. RESULTS: Among 31 patients with confirmed cHL, the median age was 19 years (range, 2-51 years) and 22 (71%) were male. Sixteen patients (52%) had stage III/IV, 25 (81%) B symptoms, and 16 (52%) performance status impairment. Twenty-three patients (74%) had symptoms >6 months, and 11 of 29 (38%) had received empiric antituberculosis treatment. Anemia was common with median hemoglobin 8.2 g/dL (range, 3.1-17.1 g/dL), which improved during treatment. No children and 5 of 15 adults (33%) were HIV+. All HIV+ patients were on antiretroviral therapy for a median 15 months (range, 2-137 months), with median CD4 count 138 cells/μL (range, 23-329 cells/μL) and four (80%) having undetectable HIV. EBV was present in 18 of 24 (75%) tumor specimens, including 14 of 20 (70%) HIV- and 4 of 4 (100%) HIV+. Baseline plasma EBV DNA was detected in 25 of 28 (89%) patients, with median viral load 4.7 (range, 2.0-6.7) log10 copies/mL, and subsequently declined in most patients. At 12 months, overall survival was 75% (95% confidence interval [CI], 55%-88%) and progression-free survival 65% (95% CI, 42%-81%). Baseline plasma EBV DNA and persistent viremia during treatment were associated with poorer outcomes. CONCLUSION: cHL in Malawi is characterized by delayed diagnosis and advanced disease. Most cases were EBV associated and one-third of adults were HIV+. Despite resource limitations, 12-month outcomes were good.
BACKGROUND: Contemporary descriptions of classical Hodgkin lymphoma (cHL) are lacking from sub-Saharan Africa where humanimmunodeficiency virus (HIV) and Epstein-Barr virus (EBV) are prevalent. METHODS: We describe a prospective cHL cohort in Malawi enrolled from 2013 to 2015. Patients received standardized treatment and evaluation, including HIV status and EBV testing of tumors and plasma. RESULTS: Among 31 patients with confirmed cHL, the median age was 19 years (range, 2-51 years) and 22 (71%) were male. Sixteen patients (52%) had stage III/IV, 25 (81%) B symptoms, and 16 (52%) performance status impairment. Twenty-three patients (74%) had symptoms >6 months, and 11 of 29 (38%) had received empiric antituberculosis treatment. Anemia was common with median hemoglobin 8.2 g/dL (range, 3.1-17.1 g/dL), which improved during treatment. No children and 5 of 15 adults (33%) were HIV+. All HIV+ patients were on antiretroviral therapy for a median 15 months (range, 2-137 months), with median CD4 count 138 cells/μL (range, 23-329 cells/μL) and four (80%) having undetectable HIV. EBV was present in 18 of 24 (75%) tumor specimens, including 14 of 20 (70%) HIV- and 4 of 4 (100%) HIV+. Baseline plasma EBV DNA was detected in 25 of 28 (89%) patients, with median viral load 4.7 (range, 2.0-6.7) log10 copies/mL, and subsequently declined in most patients. At 12 months, overall survival was 75% (95% confidence interval [CI], 55%-88%) and progression-free survival 65% (95% CI, 42%-81%). Baseline plasma EBV DNA and persistent viremia during treatment were associated with poorer outcomes. CONCLUSION: cHL in Malawi is characterized by delayed diagnosis and advanced disease. Most cases were EBV associated and one-third of adults were HIV+. Despite resource limitations, 12-month outcomes were good.
Authors: Emilie Lanoy; Philip S Rosenberg; Fabien Fily; Anne-Sophie Lascaux; Valerie Martinez; Maria Partisani; Isabelle Poizot-Martin; Elisabeth Rouveix; Eric A Engels; Dominique Costagliola; James J Goedert Journal: Blood Date: 2011-05-06 Impact factor: 22.113
Authors: Satish Gopal; Monita R Patel; Chad J Achenbach; Elizabeth L Yanik; Stephen R Cole; Sonia Napravnik; Greer A Burkholder; W Christopher Mathews; Benigno Rodriguez; Steven G Deeks; Kenneth H Mayer; Richard D Moore; Mari M Kitahata; Kristy L Richards; Joseph J Eron Journal: Clin Infect Dis Date: 2014-04-21 Impact factor: 9.079
Authors: Martin Spacek; Petr Hubacek; Jana Markova; Miroslav Zajac; Zdenka Vernerova; Katerina Kamaradova; Jan Stuchly; Tomas Kozak Journal: APMIS Date: 2010-10-25 Impact factor: 3.205
Authors: Marcus Hentrich; Marcel Berger; Christoph Wyen; Jan Siehl; Jürgen K Rockstroh; Markus Müller; Gerd Fätkenheuer; Elisabeth Seidel; Maike Nickelsen; Timo Wolf; Ansgar Rieke; Dirk Schürmann; Ralf Schmidmaier; Manfred Planker; Jürgen Alt; Franz Mosthaf; Andreas Engert; Keikawus Arasteh; Christian Hoffmann Journal: J Clin Oncol Date: 2012-10-08 Impact factor: 44.544
Authors: Satish Gopal; Monita R Patel; Elizabeth L Yanik; Stephen R Cole; Chad J Achenbach; Sonia Napravnik; Greer A Burkholder; Erin G Reid; Benigno Rodriguez; Steven G Deeks; Kenneth H Mayer; Richard D Moore; Mari M Kitahata; Joseph J Eron; Kristy L Richards Journal: J Natl Cancer Inst Date: 2013-07-26 Impact factor: 13.506
Authors: Christopher C Stanley; Kate D Westmoreland; Salama Itimu; Ande Salima; Toon van der Gronde; Peter Wasswa; Idah Mtete; Mercy Butia; Nader K El-Mallawany; Satish Gopal Journal: Pediatr Blood Cancer Date: 2016-11-28 Impact factor: 3.167
Authors: Tamiwe Tomoka; Nathan D Montgomery; Eric Powers; Bal Mukunda Dhungel; Elizabeth A Morgan; Maurice Mulenga; Satish Gopal; Yuri Fedoriw Journal: Clin Lab Med Date: 2017-12-13 Impact factor: 1.935
Authors: Christopher C Stanley; Toon van der Gronde; Kate D Westmoreland; Ande Salima; Amy Amuquandoh; Salama Itimu; Agness Manda; Idah Mtete; Mercy Butia; Atupele Mpasa; Stella Wachepa; Paula Fox; Peter Wasswa; Peter Kazembe; Nader K El-Mallawany; Satish Gopal Journal: Support Care Cancer Date: 2017-10-07 Impact factor: 3.603
Authors: Grace K Ellis; Agness Manda; Hillary Topazian; Christopher C Stanley; Ryan Seguin; Caroline E Minnick; Blessings Tewete; Asekanadziwa Mtangwanika; Mena Chawinga; Sara Chiyoyola; Maria Chikasema; Ande Salima; Stephen Kimani; Edwards Kasonkanji; Victor Mithi; Bongani Kaimila; Matthew S Painschab; Satish Gopal; Katherine D Westmoreland Journal: Int Health Date: 2021-04-27 Impact factor: 2.473
Authors: Bongani Kaimila; Toon van der Gronde; Christopher Stanley; Edwards Kasonkanji; Maria Chikasema; Blessings Tewete; Paula Fox; Satish Gopal Journal: Infect Agent Cancer Date: 2017-08-09 Impact factor: 2.965
Authors: Nathan D Montgomery; Cara Randall; Matthew Painschab; Ryan Seguin; Bongani Kaimila; Edwards Kasonkanji; Takondwa Zuze; Robert Krysiak; Marcia K Sanders; Avian Elliott; Melissa B Miller; Coxcilly Kampani; Fred Chimzimu; Maurice Mulenga; Blossom Damania; Tamiwe Tomoka; Yuri Fedoriw; Dirk P Dittmer; Satish Gopal Journal: Cancer Med Date: 2019-11-29 Impact factor: 4.452